Results 101 to 110 of about 12,390 (209)

Head and Neck Lymph Node Metastases From Cancer of Unknown Primary: Outcomes From p16‐Guided Mucosal Radiotherapy

Head &Neck, EarlyView.
ABSTRACT Background The AJCC 8th edition distinguishes p16‐positive oropharyngeal head and neck carcinoma of unknown primary (HNCUP) due to its superior prognosis. However, standardized radiation volume guidelines are lacking. This study evaluates the safety of p16‐guided mucosal volume reduction.
Philippe Harris, Dhiya‐Eddine Mabrouki, Felix‐Phuc Nguyen‐Tan, Edith Filion, Olivier Ballivy, Brian O'Sullivan, Apostolos Christopoulos, Tareck Ayad, Louis Guertin, Eric Bissada, Paul Tabet, Denis Soulières, Antoine Desilets, Alexandre Pellan Cheng, Robert Doucet, Laurent Létourneau‐Guillon, Houda Bahig   +16 more
wiley   +1 more source

Pattern of Failure in Nasopharyngeal Carcinoma After Radiotherapy in a Low‐Incidence Population: A DAHANCA Study

Head &Neck, EarlyView.
ABSTRACT Background Nasopharyngeal carcinoma (NPC) is uncommon in many populations. Most existing clinical evidence comes from endemic areas, where Epstein–Barr virus (EBV)‐associated subtypes predominate. We analyzed patterns of failure in a population‐based cohort from Denmark, a low‐incidence setting.
Anne Marie Lindegaard, Katrin Haakansson, Maria Andersen, Mogens Bernsdorf, Jesper G. Eriksen, Mohammad Farhadi, Lisa L. Hjalgrim, Kenneth Jensen, Giedrius Lelkaitis, Christian Maare, Jens Overgaard, Christina Caroline Plaschke, Erik Schiess, Ruta Zukuskaite, Jeppe Friborg   +14 more
wiley   +1 more source

Predictors of Delayed and Omitted Postoperative Radiotherapy After Laryngectomy for pT4 Laryngeal Cancer

Head &Neck, EarlyView.
ABSTRACT Background Postoperative radiotherapy (PORT) improves locoregional control and survival in high‐risk head and neck cancer, and guidelines recommend initiation within 42 days of surgery. Timeliness after laryngectomy for pathologic T4 (pT4) laryngeal cancer is poorly characterized.
George Ashji, Arun Rajan, Elias Dahl, Sudarshan Ramanan, Nishant Chadha, Yingzhi Wu, Richard J. Wong, Marc A. Cohen, Edward Christopher Dee, Nancy Y. Lee   +9 more
wiley   +1 more source

Treatment Patterns and Survival Outcomes of Head and Neck Merkel Cell Carcinoma: An Age‐Stratified Analysis

Head &Neck, EarlyView.
ABSTRACT Background H&N Merkel cell carcinoma (MCC) mainly affects elderly patients, yet age‐stratified treatment patterns and outcomes data are scarce. Methods We analyzed 88 consecutive H&N MCC patients (2000–2022) by age (< 75 vs. ≥ 75 years). OS was estimated by Kaplan–Meier analysis and MCC‐specific death with competing‐risks methods (cause ...
Igor Vainer, Lior Strinkovsky, Eyal Fenig, Gideon Bachar   +3 more
wiley   +1 more source

Development and characterization of phantoms to investigate the Flash effect with <i>Drosophila melanogaster</i> at an ultra-high dose rate radiotherapy linac. [PDF]

Phys Imaging Radiat Oncol
Dal Bello R, Kreuzer M, Vetrugno I, Little JC, Kranzer R, Schischke S, Bossin L, Yukihara EG, Guckenberger M, Pruschy M, Tanadini-Lang S.   +10 more
europepmc   +1 more source

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

International Journal of Cancer, EarlyView.
ABSTRACT Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen ...
Lorena Incorvaia, Daniele Santini, Marc R. Matrana, Marco Maruzzo, Ray Manneh Kopp, Lorenzo Antonuzzo, Sergio Bracarda, Deniz Tural, Giuseppe Procopio, Maria T. Bourlon, Orazio Caffo, Martin Ignacio Zapata Laguado, Massimo Di Maio, Brigida Anna Maiorano, Vincenza Conteduca, Sabrina Rossetti, Helga Lipari, Thomas Büttner, Mimma Rizzo, Yüksel Ürün, Carlo Messina, Fernando Sabino Marques Monteiro, Andrey Soares, Mattia Puglisi, Alice Principi, Eleonora Lai, Giulia Mammone, Marco Stellato, Ilaria Depetris, Tancredi Didier Bazan Russo, Isadora Yasbick Spricido, Camila Bobato Lara Gismondi, Francesco Massari, Nicola Pavan, Matteo Santoni, Tarek Taha   +35 more
wiley   +1 more source

Diabetes Increases Immunotherapy‐Related Toxicity but Not Efficacy in Metastatic Non‐Small Cell Lung Cancer: A Multicenter Retrospective Study

International Journal of Cancer, EarlyView.
ABSTRACT This multicenter retrospective study evaluated the impact of type 2 diabetes mellitus (DM) on clinical outcomes and immune‐related adverse events (irAEs) in 450 patients with metastatic non‐small cell lung cancer (NSCLC) treated with second‐line nivolumab at 17 centers between 2016 and 2024. Among these patients, 118 (26.2%) had DM.
Emre Çakır, Didem Divriklioğlu, Deniz Can Güven, Gamze Serin Özel, Oğuzhan Yıldız, Gamze Emin, Merve Keskinkılıç, Yeşim Ağyol, Onur Yazdan Balçık, Nagihan Kolkıran, Hale Gülçin Yıldırım Doğan, Pervin Can Şancı, Özge Yalıcı, Teoman Şakalar, Yurdagül Danacı, Yakup Düzköprü, Canan Yıldız, Mesut Yılmaz, İlhan Hacıbekiroğlu, Bülent Erdoğan, Saadettin Kılıçkap, Gamze Gököz Doğu, Melek Karakurt Eryılmaz, Atila Yıldırım, İlhan Öztop, İbrahim Vedat Bayoğlu, Şahnura Uzuntaş, Atike Pınar Erdoğan, Emir Çelik, Devrim Çabuk, Erdoğan Selçuk Şeber, Zehra Sadak Öcal, Hacer Demir   +32 more
wiley   +1 more source

Early Cessation of Adjuvant Anti‐PD‐1 Therapy in Stage III and IV Melanoma

International Journal of Cancer, EarlyView.
ABSTRACT One year of adjuvant anti‐PD‐1 has improved disease‐free survival in Stage III melanoma. It is unknown whether shorter treatment duration affects outcomes. Real‐world data may help clarify this. In this retrospective observational study, patients with resected Stage III/IV melanoma receiving adjuvant anti‐PD‐1 in the Netherlands from 2018 to ...
Manja Bloem, Melissa M. de Meza, Cato D. M. Boreel, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Willeke A. M. Blokx, Marye J. Boers‐Sonderen, Han J. Bonenkamp, Jan Willem B. de Groot, John B. Haanen, Geke A. P. Hospers, Ellen Kapiteijn, Djura Piersma, Bart Rikhof, Lieke H. J. Simkens, Marion A. Stevense‐den Boer, Astrid A. M. van der Veldt, Karijn P. M. Suijkerbuijk, Alfonsus J. M. van den Eertwegh, Michel W. J. M. Wouters   +20 more
wiley   +1 more source

Real‐World Experience With Multimodal Treatment of Resectable Stage II–III Non‐Small Cell Lung Cancer: A Single Institutional Analysis

International Journal of Cancer, EarlyView.
ABSTRACT Neoadjuvant therapy has recently become an integral component of multimodal treatment for resectable lung cancer. However, real‐world data on perioperative morbidity and treatment adherence remain limited. This study aimed to assess the feasibility and safety of different neoadjuvant treatment approaches applied within daily clinical routine ...
Raffaella Griffo, Benedikt Niedermaier, Laura V. Klotz, Marc Schneider, Michael Allgäuer, Marc Kriegsmann, Romina M. Roesch, Lena Brendel, Henrike Deissner, Farastuk Bozorgmehr, Petros Christopoulos, Michael Thomas, Hauke Winter, Martin E. Eichhorn, Florian Eichhorn   +14 more
wiley   +1 more source

First Monte Carlo beam model for ultra-high dose rate radiotherapy with a compact electron LINAC. [PDF]

Med Phys
Dai T, Sloop AM, Rahman MR, Sunnerberg JP, Clark MA, Young R, Adamczyk S, Von Voigts-Rhetz P, Patane C, Turk M, Jarvis L, Pogue BW, Gladstone DJ, Bruza P, Zhang R.   +14 more
europepmc   +1 more source